Observational studyThe Journal of dermatology2022

Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan.

Nobukazu Hayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.